Supplementary Figure 3 from Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate

Supplemental Figure 3. Validation of RNA seq results of responders by Nanostring nCounter gene expression assay